Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | TP53 | P04637 | 4/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173989 | 0.86 | MAPT (0.76) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL12980459 | 0.85 | MAPT (0.75) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL25916294 | 0.83 | HPGD (0.78) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL30362646 | 0.83 | HPGD (0.78) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL12963275 | 0.80 | MAPT (0.72) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL12963284 | 0.79 | MAPT (0.71) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL12963290 | 0.78 | MAPT (1.00) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL12217966 | 0.78 | ALDH1A1 (0.59) | MAPTTP53HPGDTSHRHSD17B10 | |
| SCHEMBL12963282 | 0.77 | HPGD (0.68) | MAPTTP53RXFP1HPGDTSHR | |
| SCHEMBL25208976 | 0.76 | MAPT (0.68) | MAPTTP53RXFP1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2011002635-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | HAVCR2, TTPA, CHIA | MAPT 118/4885TP53 2739/4885RXFP1 4348/4885 |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | HAVCR2, TTPA, CHIA | MAPT 118/4885TP53 2739/4885RXFP1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.